Although the Biologics Price Competition and Innovation Act (BPCIA) was enacted several years ago, activity under the BPCIA was sparse, and limited primarily to U.S. Food and Drug Administration (FDA) draft guidance. This inactivity led to speculation as to how the FDA, reference product sponsors, and biosimilar applicants would implement the BPCIA regulatory and prelitigation provisions. Well, the speculation is over. There has been a plethora of activity over the past several months concerning the BPCIA. Please join our panelists as they discuss issues relating to:
RSVP: Space is limited. To attend, please register by May 4, 2015.
Thursday, May 7, 2015
9:15 a.m. - 9:45 a.m. – Registration and Breakfast
9:45 a.m. - 12:00 p.m. – Workshop
12:00 p.m. - 12:30 p.m. – Working Lunch
12:30 p.m. - 3:00 p.m. – Workshop
Location:
Finnegan
Two Seaport Lane
Boston, MA 02210
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.